{"schema_version":"secwatch.filing_event.v1","accession":"0000899923-24-000005","form_type":"8-K","ticker":"MYGN","cik":"0000899923","company_name":"MYRIAD GENETICS INC","filed_at":"2024-01-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.229107+00:00","generated_at":"2026-06-06T23:44:09.780192+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Myriad Genetics prelim Q4 revenue $196-197M; GAAP EPS loss ($0.35)-($0.36); adjusted EPS $0.02-0.03","bullets":["Preliminary Q4 2023 revenue $196-197M; GAAP diluted EPS loss ($0.35)-($0.36); adjusted EPS $0.02-$0.03.","FY2023 revenue growth reaffirmed at least 10% YoY; prenatal volume growth at least 10% in Q4.","Reaffirmed positive adjusted operating cash flow in Q4 2023; guided estimated cash and credit at year-end.","Excluded items for non-GAAP: stock-based comp ~$10.3M, amortization ~$10.7M, transformation costs ~$14.1M, legal ~$0.6M, tax ~$2.0M.","Reaffirmed FY2023 revenue and non-GAAP guidance originally provided on Nov 6, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000899923-24-000005","json":"https://secwatch.observer/filing/0000899923-24-000005.json","markdown":"https://secwatch.observer/filing/0000899923-24-000005.md","text":"https://secwatch.observer/filing/0000899923-24-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899923/000089992324000005/0000899923-24-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899923/000089992324000005/mygn-20240110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T23:44:09.780192+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4af0cb436147fdcf011a154b32fc01c96bd1ee80","claim":"MYRIAD GENETICS INC reported fourth quarter 2023 results: revenue between approximately $196 and $197 million, EPS diluted GAAP earnings per share of between ($0.35) an d ($0.36), adj usted earnings per share of between $0.02 and $0.03. Guidance reaffirmed.","evidence_excerpt":"The Company also disclosed preliminary financial data for the fourth quarter of 2023, specifically that the Company expects fourth quarter 2023 revenue of between approximately $196 and $197 million, diluted GAAP earnings per share of between ($0.35) an d ($0.36), adj usted earnings per share of between $0.02 and $0.03, and GAAP and adjusted gross margin of approximately 70%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/899923/000089992324000005/0000899923-24-000005-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter 2023"},{"label":"Revenue","value":"between approximately $196 and $197 million"},{"label":"EPS","value":"diluted GAAP earnings per share of between ($0.35) an d ($0.36), adj usted earnings per share of between $0.02 and $0.03"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}